Brokerages Set Altimmune, Inc. (NASDAQ:ALT) PT at $16.67

Altimmune, Inc. (NASDAQ:ALT) has been given a consensus rating of “Moderate Buy” by the ten analysts that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $16.6667.

A number of equities analysts recently issued reports on ALT shares. B. Riley Financial dropped their target price on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Friday, March 27th. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Truist Financial started coverage on shares of Altimmune in a research report on Wednesday, March 18th. They set a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price (down from $25.00) on shares of Altimmune in a research report on Monday, May 18th.

Insider Transactions at Altimmune

In related news, CEO Jerome Benedict Durso bought 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average price of $3.54 per share, with a total value of $70,800.00. Following the completion of the transaction, the chief executive officer owned 32,500 shares of the company’s stock, valued at $115,050. The trade was a 160.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Altimmune by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after buying an additional 2,241 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Altimmune during the first quarter worth $50,000. Envestnet Asset Management Inc. boosted its stake in Altimmune by 48.0% during the second quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock worth $127,000 after buying an additional 10,671 shares in the last quarter. Creative Planning boosted its stake in Altimmune by 30.2% during the second quarter. Creative Planning now owns 41,164 shares of the company’s stock worth $159,000 after buying an additional 9,558 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Altimmune by 7.0% during the second quarter. Rhumbline Advisers now owns 113,981 shares of the company’s stock worth $441,000 after buying an additional 7,462 shares in the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Up 3.0%

Shares of ALT stock opened at $3.07 on Friday. Altimmune has a 12 month low of $2.56 and a 12 month high of $7.73. The firm has a market cap of $597.02 million, a PE ratio of -3.30 and a beta of 0.18. The stock has a 50 day moving average of $3.12 and a 200-day moving average of $4.03. The company has a quick ratio of 29.56, a current ratio of 29.56 and a debt-to-equity ratio of 0.12.

Altimmune (NASDAQ:ALT) last announced its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. On average, equities analysts predict that Altimmune will post -0.69 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.